Khalid El Bairi: Our TASMAN study on the use of medical cannabis in oncology
Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared a post on LinkedIn about a recent paper by him and colleagues published in the European Journal of Cancer:
“Our TASMAN study on the use of medical cannabis in oncology is finally published in the European Journal of Cancer.
Have a look! The findings are interesting.
Great job by my colleagues Dario Trapani and Raffaele Giusti.”
Authors: Dario Trapani, Sara Nidhamalddin, Sara Gandini, Khalid El Bairi, Giuseppe Curigliano, Raffaele Giusti et al.
More posts featuring Khalid El Bairi.
Khalid El Bairi, founder of The Cancer Biomarkers Working Group, specializes in clinical and translational research in medical oncology. With many peer-reviewed articles, he delves into predictive and prognostic cancer biomarkers, especially for digestive and gynecological cancers like ovarian and colorectal malignancies.
El Bairi holds board positions in international scientific societies such as IGCS, ESMO, ASCO, ESGO, and AACR. Serving as editor and reviewer for over 40 journals, he also educates medical and Ph.D. students on evidence-based medicine, research methodologies, and publishing ethics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023